Skip to content
Clinical Trials – home

Dermastyle S.R.L.

Verified siteinfo

Romania Soseaua Bucuresti-Ploiesti 69-71, 013685 Bucharest, Romania

  • 6 trials recruiting
  • Colitis ulcerative · Crohn's disease · Dermatitis atopic
  • Adults and children

About Specializations

Dermastyle S.R.L. in Bucharest, Romania specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Dermatitis atopic, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases Research

The Dermatovenerology department at Dermastyle S.R.L. concentrates on immune system diseases, with a particular focus on Atopic Dermatitis. Ongoing studies aim to test new therapeutic approaches that could better control symptoms and improve quality of life.

  • Evaluation of the novel biologic rocatinlimab for moderate‑to‑severe eczema
  • Use of the Eczema Area and Severity Index (EASI) to measure treatment impact
  • Long‑term safety and effectiveness assessment in adolescent patients
  • Investigation of underlying immune mechanisms driving atopic skin inflammation

Located in Bucharest, Romania, the site conducts its trials with a dedicated investigator team, seeking to bring advanced therapies to those affected by atopic dermatitis.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Soseaua Bucuresti-Ploiesti 69-71013685 BucharestRomania
Recruiting now
6 trials
Conditions studied
3
Partner status
Verified site

More sites in BucharestRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:RomaniaRomania
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.